

Cited in: *EMBASE/Excerpta Medica, Oncology Information Service, Elsevier BIOBASE/Current Awareness in Biological Sciences; Current Contents/Clinical Medicine; SciSearch, Index Medicus/MEDLINE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.*

Reviews

- Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society**
P. Rajadurai, P.L. Cheah, S.H. How, C.K. Liam, M.A.A. Annuar, N. Omar, N. Othman, N.M. Marzuki, Y.K. Pang, R.S.A. Bustamam, L.M. Tho (Malaysia) 65

Original Research Articles

- PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer**
G. Wang, D.N. Ionescu, C.-H. Lee, T. Hiruki, R. Myers, T. Shaipanich, S. Lam, B. Melosky, C. Zhou (Canada) 1
- EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations**
W. Tang, X. Li, X. Xie, X. Sun, J. Liu, J. Zhang, C. Wang, J. Yu, P. Xie (China) 6
- The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma**
Y. Lee, J.H. Jeon, S.-H. Goh, H. Roh, J.-Y. Yun, N.-J. Kwon, J.H. Choi, H.C. Yang, M.S. Kim, J.M. Lee, G.K. Lee, J.-Y. Han (Republic of Korea) 15
- Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients**
Z. Song, W. Wang, M. Li, J. Liu, Y. Zhang (China) 23
- Dynamic changes in PD-L1 expression and CD8⁺ T cell infiltration in non-small cell lung cancer following chemoradiation therapy**
E.-A. Choe, Y.J. Cha, J.-H. Kim, K.H. Pyo, M.H. Hong, S.Y. Park, H.S. Shim, I. Jung, C.Y. Lee, B.C. Cho, H.R. Kim (Republic of Korea) 30
- Clinicopathologic features and lymph node metastatic characteristics in patients with adenocarcinoma manifesting as part-solid nodule exceeding 3 cm in diameter**
W. Li, F. Zhou, Z. Wan, M. Li, Y. Zhang, X. Bao, L. Zhang, J. Shi (China) 37
- Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors**
F. Shoji, H. Takeoka, Y. Kozuma, G. Toyokawa, K. Yamazaki, M. Ichiki, S. Takeo (Japan) 45
- A phase II study of *nab*-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer**
L.C. Villaruz (USA), M. Cobo (Spain), K. Syrigos, D. Mavroudis (Greece), W. Zhang, J.S. Kim, M.A. Socinski (USA) 52
- Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma**
T. Ichikawa, K. Aokage, T. Miyoshi, K. Tane, K. Suzuki, H. Makinoshima, M. Tsuboi, G. Ishii (Japan) 57

(Contents continued overleaf)



| | |
|--|-----|
| An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer | |
| D. Morgensztern (USA), N. Karaseva (Russian Federation), E. Felip, I. Delgado (Spain), O. Burdaeva (Russian Federation), M. Dómine (Spain), P. Lara, P.K. Paik (USA), U. Lassen (Denmark), S. Orlov (Russian Federation), J. Trigo (Spain), M. Shomova (Russian Federation), K. Baker-Neblett, J. Vasquez, X. Wang, L. Yan, I. Mitrica, M.P. DeYoung (USA), P. Garrido (Spain) | 74 |
| Galectin-9 in non-small cell lung cancer | |
| Y. He, K. Jia (People's Republic of China), R. Dziadziuszko (Poland), S. Zhao, X. Zhang, J. Deng, H. Wang (People's Republic of China), F.R. Hirsch (USA), C. Zhou (People's Republic of China) | 80 |
| EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice | |
| H. Higo, K. Ohashi, G. Makimoto, K. Nishii, K. Kudo, H. Kayatani, H. Watanabe, H. Kano, K. Ninomiya, K. Hotta, Y. Maeda, K. Kiura (Japan) | 86 |
| Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study) | |
| R. Descourt, M. Perol, G. Rousseau-Bussac, D. Planchard, B. Menecier, M. Wislez, A. Cortot, F. Guisier, L. Galland, P. Dô, R. Schott, E. Dansin, J. Arrondeau, J.-B. Auliac, C. Chouaid (France) | 109 |
| Increased risk of coronary heart disease and stroke in lung cancer survivors: A Korean nationwide study of 20,458 patients | |
| D.W. Yoon, D.W. Shin, J.H. Cho, J.H. Yang (Republic of Korea), S.-M. Jeong (Republic of Korea, USA), K. Han, S.H. Park (Republic of Korea) | 115 |
| A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer | |
| Y.-J. Kim, B. Keam, C.-Y. Ock, S. Song, M. Kim, S.H. Kim, K.H. Kim, J.-S. Kim, T.M. Kim, D.-W. Kim, J.S. Lee, D.S. Heo (Republic of Korea) | 122 |
| Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation | |
| J. Jin, Y. Gan, H. Liu, Z. Wang, J. Yuan, T. Deng, Y. Zhou, Y. Zhu, H. Zhu, S. Yang, W. Shen, D. Xie, H. Wu, D. Liu, W. Li (China) | 129 |
| PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer | |
| R. Sumitomo, T. Hirai, M. Fujita, H. Murakami, Y. Otake, C.-I. Huang (Japan) | 136 |
| <i>Short Communications</i> | |
| Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores | |
| K. Zhou, C. Jiang, Q. Li (China) | 98 |
| Performance of community-based lung cancer screening program in a Histoplasma endemic region | |
| S. Bhandari, P. Tripathi, D. Pham, C. Pinkston, G. Kloecker (USA) | 102 |
| Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey | |
| A. Levy (France), L.E.L. Hendriks (the Netherlands), C. Le Pêchoux (France), S. Falk (United Kingdom), B. Besse (France), S. Novello (Italy), A.-M.C. Dingemans (the Netherlands), B. Hasan (Belgium), M. Reck (Germany), T. Berghmans (Belgium), C. Faivre-Finn (United Kingdom) | 145 |
| <i>Case Reports</i> | |
| A case of invasive mucinous adenocarcinoma of the lung showing stepwise progression at the primary site | |
| H. Kawai, M. Sugano, N. Nakano, M. Muratani, S. Sakashita, Y. Goto, M. Noguchi (Japan) | 94 |
| A case of primary lung squamous cell carcinoma mimicking malignant mesothelioma producing granulocyte colony stimulating factor with chemotherapy (cisplatin and gemcitabine)-associated thrombotic thrombocytopenic purpura (TTP); An autopsy case report | |
| Y. Suzuki, K. Kanazawa, R. Kanai, H. Tomita, M. Saito, N. Watanabe, J. Morimoto, T. Umeda, T. Kawamata, M. Rikimaru, T. Koizumi, R. Togawa, Y. Sato, K. Hirai, M. Uematsu, H. Minemura, T. Nikaïdo, A. Fukuhara, S. Sato, J. Saito, Y. Tanino, K. Mori, Y. Shibata (Japan) | 105 |

(Contents continued overleaf)

Correspondence

- Comment on: "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos"**
E.J.A. Harris, A.W. Musk, N. DeKlerk, F.J.H. Brims (Australia) 148
- Comment on: "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos"**
F. Barbone, F. Barbiero, G. Fasola (Italy) 150
- Response to comment on: "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos"**
P. Maisonneuve, S. Iavicoli, G. Veronesi (Italy) 151
- Primary resistance to icotinib in a patient with lung adenocarcinoma harboring *EGFR* L858R and Q787k mutations**
W. Heng, C. You, C. Shangli, Q. Chuang, X. Mingzhe (China) 153
- Errata*
- Erratum to "Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases" [Lung Cancer 116 (February 2018) 62-66]**
C. Gauvain, E. Vauléon, C. Chouaid, E. Le Rhun, L. Jabot, A. Scherpereel, F. Vinas, A.B. Cortot, I. Monnet (France) 159
- Erratum to "High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors" [Lung Cancer 132 (June) (2019) 9-16]**
G.J. Lee, H. Lee, I.S. Woo, T. Kim, H.J. An, H.J. Choi, Y.S. Lee, K.Y. Lee, J. Lee, J.-H. Kang (South Korea) 160
- Erratum to "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma" [Lung Cancer 132 (June) (2019) 36-38]**
H. Wang, J. Agulnik, G. Kasymjanova, P.O. Fiset, S. Camilleri-Broet, M. Redpath, V. Cohen, D. Small, C. Pepe, L. Sakr, A. Spatz (Canada) 161
- Corrigenda*
- Corrigendum to "Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features" [Lung Cancer 135 (September) (2019) 1-9]**
M. Khorrami, P. Jain, K. Bera, M. Alilou, R. Thawani, P. Patil, U. Ahmad, S. Murthy, K. Stephans, P. Fu, V. Velcheti, A. Madabhushi (USA) 156
- Corrigendum to "Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation" [Lung Cancer 135 (September) (2019) 16-20]**
J.N. Bodor, J.L. Feliciano, M.J. Edelman (United States) 157
- Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]**
H. Maymani, K. Hess, R. Groisberg, D.S. Hong, A. Naing, S. Piha-Paul, F. Janku, S. Fu, A.M. Tsimberidou, S. Pant, D. Karp, S. Liu, M. Sun, J. Heymach, G. Simon, F. Meric-Bernstam, V. Subbiah (USA) 158